EpiVax Releases AI-Enhanced Models for Immunogenicity Prediction
EpiVax, Inc. has enhanced its ISPRI platform for assessing immunogenicity risk in biotherapeutics with artificial intelligence. The update introduces an improved JanusMatrix model.
PROVIDENCE, R.I. – EpiVax, Inc. has integrated artificial intelligence enhancements into its ISPRI platform, a proprietary in silico system used for evaluating the immunogenicity risk of biotherapeutics. The goal is to provide researchers and drug developers with tools for predicting potential immune responses.
The latest update includes an improved JanusMatrix model. This model is a core component of EpiVax's technological offerings, designed to identify and forecast the immunological reactions that biological drugs may elicit in patients.
Immunogenicity is a critical consideration in the development of biotherapeutics, as it can significantly impact a drug's efficacy and safety profile. The ability to predict adverse immune responses early in the development process can mitigate risks and reduce costs for pharmaceutical companies.
EpiVax states that the incorporation of AI into the ISPRI platform allows for more accurate and rapid predictions compared to traditional methods. This advancement could potentially accelerate the timeline for bringing new biotherapeutics to market.